Autopsy report · NCT02723838

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

“Company has reprioritized clinical plans to focus on later-stage studies.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Oncolytics Biotech

Sponsor type

Industry

Conditions

Muscle-invasive Transitional Cell Carcinoma of the Bladder

Interventions

REOLYSIN®; Gemcitabine; Cisplatin

Participants

0

Trials that died the same way

• Combined Therapeutic Air Mixture and Electrical Stimulation to Improve Breathing and Hand Function in Spinal Cord Injury
  “The study evolved into a multi day clinical trial and was recently awarded an extramural funding. The new study will begin enrollment in late August 2025” (64% match in meaning)
• Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
  “Change in the clinical development plan” (63% match in meaning)
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
  “the change of clinical development plan” (63% match in meaning)
• Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis
  “The closure of the study is driven by the decision to redesign the study protocol for future studies.” (61% match in meaning)
• OsseoFit™ Prospective Data Collection
  “Planning new study protocol” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.